Modifying superparamagnetic iron oxides nanoparticles for doxorubicin delivery carriers: a review
Source abstract
Abstract
Cancer—one of the most life-threatening human diseases—can be treated with surgery, chemotherapy, and radiotherapy. Despite the negative side effects, conventional chemotherapy which contains doxorubicin is widely used in cancer treatment. Drug delivery carriers, an alternative cancer treatment, can be used to target tumor site by vectorizing anti-cancer drug and minimize the drug quantities. Due to unique physical and chemical properties, superparamagnetic iron oxide nanoparticles are researched and documented. This work investigates how magnetic drug delivery carriers are synthesized, how the carriers are characterized and quantified, the mechanisms of drug loading/releasing of the carriers including kinetics and thermodynamic parameters, and the future research topics of magnetic drug delivery carriers for loading and releasing doxorubicin.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Iron oxide chemistry and applications · Magnetic Properties and Synthesis of Ferrites
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Senkus E, Jassem J (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37(4):300–31110.1016/j.ctrv.2010.11.001 ↗
2. Kucharska W, Negrusz-Kawecka M, Gromkowska M (2012) Cardiotoxicity of oncological treatment in children. Adv Clin Exp Med 21(3):281–288
3. Doan L, Lu Y, Karatela M et al (2019) Surface modifications of superparamagnetic iron oxide nanoparticles with polylactic acid-polyethylene glycol diblock copolymer and graphene oxide for a protein delivery vehicle. Engineered Science (7):10–16. https://doi.org/10.30919/es8d51010.30919/es8d510 ↗
4. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer 2(1):48–5810.1038/nrc706 ↗
5. Jin S, Ye K (2013) Targeted drug delivery for breast cancer treatment. Recent Pat Anticancer Drug Discov 8(2):143–15310.2174/1574892811308020003 ↗
6. Minotti G, Saponiero A, Licata S et al (2001) Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 7(6):1511–1515
7. Kalyanaraman B (2020) Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree? Redox Biol 29:10139410.1016/j.redox.2019.101394 ↗
8. Hoke EM, Maylock CA, Shacter E (2005) Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radical Biol Med 39(3):403–41110.1016/j.freeradbiomed.2005.03.029 ↗
9. Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems: Doxorubicin cell and molecular biological activity. J Pharm Pharmacol 65(2):157–17010.1111/j.2042-7158.2012.01567.x ↗
10. Hanušová V, Boušová I, Skálová L (2011) Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug Metab Rev 43(4):540–55710.3109/03602532.2011.609174 ↗
11. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727–74110.1016/S0006-2952(98)00307-4 ↗
12. Carvalho C, Santos RX, Cardoso S et al (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16(25):3267–328510.2174/092986709788803312 ↗
13. Binaschi M, Bigioni M, Cipollone A et al (2001) Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 1(2):113–13010.2174/1568011013354723 ↗
14. Arpino G, Ciocca DR, Weiss H et al (2005) Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 92(1):69–7510.1007/s10549-005-1721-9 ↗
15. Bertheau P, Plassa F, Espié M et al (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360(9336):852–85410.1016/S0140-6736(02)09969-5 ↗
16. Clementi ME, Giardina B, Di Stasio E et al (2003) Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res 23(3B):2445–2450
17. Di Leo A, Isola J (2003) Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 4(3):179–186
18. Doroshow JH (1986) Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 135(1):330–33510.1016/0006-291X(86)90981-2 ↗
19. Dunkern TR, Wedemeyer I, Baumgärtner M et al (2003) Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair 2(1):49–6010.1016/S1568-7864(02)00185-4 ↗
20. Green PS, Leeuwenburgh C (2002) Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588(1):94–10110.1016/S0925-4439(02)00144-8 ↗
21. Guano F, Pourquier P, Tinelli S et al (1999) Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol 56(1):77–8410.1124/mol.56.1.77 ↗
22. Inoue A, Narumi K, Matsubara N et al (2000) Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett 157(1):105–11210.1016/S0304-3835(00)00480-8 ↗
23. Lage H, Dietel M (2002) Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 128(7):349–35710.1007/s00432-002-0349-y ↗
24. Lage H, Helmbach H, Dietel M et al (2000) Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 82(2):488–49110.1054/bjoc.1999.0947 ↗
25. MacGrogan G, Rudolph P, de Mascarel Id I et al (2003) DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer 89(4):666–67110.1038/sj.bjc.6601185 ↗
26. Penault-Llorca F, Cayre A, Bouchet Mishellany F et al (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22(6):1319–1325
27. Perego P, Corna E, De Cesare M et al (2001) Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 8(1):31–3710.2174/0929867013373994 ↗
28. Ramachandran C, Samy TS, Huang XL et al (1993) Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. Biochem Pharmacol 45(6):1367–137110.1016/0006-2952(93)90293-6 ↗
29. Ruiz-Ruiz C, Robledo G, Cano E et al (2003) Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. J Biol Chem 278(34):31667–3167510.1074/jbc.M304397200 ↗
30. Sinha BK, Katki AG, Batist G et al (1987) Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol 36(6):793–79610.1016/0006-2952(87)90164-X ↗
31. Stearns V, Singh B, Tsangaris T et al (2003) A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9(1):124–133
32. Lipshultz SE, Lipsitz SR, Sallan SE et al (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. JCO 23(12):2629–263610.1200/JCO.2005.12.121 ↗
33. Iarussi D, Indolfi P, Casale F et al (2005) Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Pediatr Drugs 7(2):67–7610.2165/00148581-200507020-00001 ↗
34. Sorensen K, Levitt GA, Bull C et al (2003) Late anthracycline cardiotoxicity after childhood cancer. Cancer 97(8):1991–199810.1002/cncr.11274 ↗
35. Doyle JJ, Neugut AI, Jacobson JS et al (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. JCO 23(34):8597–860510.1200/JCO.2005.02.5841 ↗
36. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900–90510.1056/NEJM199809243391307 ↗
37. Chlebowski RT (1979) Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med 131(5):364–368
38. Bristow MR, Billingham ME, Mason JW et al (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62(6):873–879
39. Zhao X, Zhang J, Tong N et al (2012) Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice. Biol Pharm Bull 35(5):796–80010.1248/bpb.35.796 ↗
40. Jacevic V, Djordjevic A, Srdjenovic B et al (2017) Fullerenol nanoparticles prevents doxorubicin-induced acute hepatotoxicity in rats. Exp Mol Pathol 102(2):360–36910.1016/j.yexmp.2017.03.005 ↗
41. Pugazhendhi A, Edison TNJI, Velmurugan BK et al (2018) Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci 200:26–3010.1016/j.lfs.2018.03.023 ↗
42. Nowara E, Huszno J (2013) Skin toxicity after palliative chemotherapy containing pegylated liposomal doxorubicin for ovarian cancer patients. Ann Palliat Med 2(2):71–75
43. Siswanto S, Arozal W, Juniantito V et al (2016) The effect of mangiferin against brain damage caused by oxidative stress and inflammation induced by doxorubicin. HAYATI J Biosci 23(2):51–5510.1016/j.hjb.2016.02.001 ↗
44. Tangpong J, Miriyala S, Noel T et al (2011) Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia Mangostana. Neuroscience 175:292–29910.1016/j.neuroscience.2010.11.007 ↗
45. Su Z, Ye J, Qin Z et al (2016) Protective effects of madecassoside against Doxorubicin induced nephrotoxicity in vivo and in vitro. Sci Rep 5(1):1831410.1038/srep18314 ↗
46. Kim DR, Lee SY, Kim JS et al (2017) Ameliorating effect of gemigliptin on renal injury in murine adriamycin-induced nephropathy. Biomed Res Int 2017:1–10
47. Kabel AM (2018) Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling. Biomed Pharmacother 97:439–44910.1016/j.biopha.2017.10.144 ↗
48. Leonard RCF, Williams S, Tulpule A et al (2009) Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet™). The Breast 18(4):218–22410.1016/j.breast.2009.05.004 ↗
49. Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8(6):473–48010.1038/nrc2394 ↗
50. Vallet-Regí M, Balas F, Arcos D (2007) Mesoporous materials for drug delivery. Angew Chem Int Ed 46(40):7548–755810.1002/anie.200604488 ↗
51. Biju V (2014) Chemical modifications and bioconjugate reactions of nanomaterials for sensing, imaging, drug delivery and therapy. Chem Soc Rev 43(3):744–76410.1039/C3CS60273G ↗
52. Kohzadi S, Najmoddin N, Baharifar H et al (2022) Functionalized SPION immobilized on graphene-oxide: anticancer and antiviral study. Diam Relat Mater 127:10914910.1016/j.diamond.2022.109149 ↗
53. Jeng HA, Swanson J (2006) Toxicity of metal oxide nanoparticles in mammalian cells. J Environ Sci Health, Part A 41(12):2699–271110.1080/10934520600966177 ↗
54. Hussain SM, Hess KL, Gearhart JM et al (2005) In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 19(7):975–98310.1016/j.tiv.2005.06.034 ↗
55. Kim JS, Yoon TJ, Yu KN et al (2006) Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 89(1):338–34710.1093/toxsci/kfj027 ↗
56. Karlsson HL, Gustafsson J, Cronholm P et al (2009) Size-dependent toxicity of metal oxide particles—a comparison between nano- and micrometer size. Toxicol Lett 188(2):112–11810.1016/j.toxlet.2009.03.014 ↗
57. Ma H-L, Qi XR, Maitani Y et al (2007) Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int J Pharm 333(1):177–18610.1016/j.ijpharm.2006.10.006 ↗
58. Rahmani R, Gharanfoli M, Gholamin M et al (2020) Plant-mediated synthesis of superparamagnetic iron oxide nanoparticles (SPIONs) using aloe vera and flaxseed extracts and evaluation of their cellular toxicities. Ceram Int 46(3):3051–305810.1016/j.ceramint.2019.10.005 ↗
59. Singh N, Jenkins GJS, Asadi R et al (2010) Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Reviews 1(1):535810.3402/nano.v1i0.5358 ↗
60. Gao S, Wu C, Jiang H et al (2014) Size-controlled porous superparamagnetic Zn1/3Fe8/3O4 nanospheres: synthesis, properties and application for drug delivery. RSC Advances 4:20841–2084610.1039/C4RA02082K ↗
61. Min KA, Shin MC, Yu F et al (2013) Pulsed magnetic field improves the transport of iron oxide nanoparticles through cell barriers. ACS Nano 7(3):2161–217110.1021/nn3057565 ↗
62. Min KA, Yu F, Yang VC et al (2010) Transcellular transport of heparin-coated magnetic iron oxide nanoparticles (Hep-MION) under the influence of an applied magnetic field. Pharmaceutics 2(2):119–13510.3390/pharmaceutics2020119 ↗
63. Domenech M, Marrero-Berrios I, Torres-Lugo M et al (2013) Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. ACS Nano 7(6):5091–510110.1021/nn4007048 ↗
64. Alexiou C, Arnold W, Klein RJ et al (2000) Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60(23):6641–6648
65. Alexiou C, Schmid RJ, Jurgons R et al (2006) Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J 35(5):446–45010.1007/s00249-006-0042-1 ↗
66. Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18):3995–402110.1016/j.biomaterials.2004.10.012 ↗
67. Pankhurst QA, Connolly J, Jones SK et al (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 36(13):R167–R18110.1088/0022-3727/36/13/201 ↗
68. Lübbe AS, Alexiou C, Bergemann C (2001) Clinical applications of magnetic drug targeting. J Surg Res 95(2):200–20610.1006/jsre.2000.6030 ↗
69. Lübbe AS, Bergemann C, Riess H et al (1996) Clinical experiences with magnetic drug targeting: a phase I study with 4’-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56(20):4686–4693
70. Mura S, Nicolas J, Couvreur P (2013) Stimuli-responsive nanocarriers for drug delivery. Nature Mater 12(11):991–100310.1038/nmat3776 ↗
71. Tassa C, Shaw SY, Weissleder R (2011) Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res 44(10):842–85210.1021/ar200084x ↗
72. Curcio A, Marotta R, Riedinger A et al (2012) Magnetic pH-responsive nanogels as multifunctional delivery tools for small interfering RNA (siRNA) molecules and iron oxide nanoparticles (IONPs). Chem Commun 48(18):240010.1039/c2cc17223b ↗
73. Yu MK, Jeong YY, Park J et al (2008) Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed 47(29):5362–536510.1002/anie.200800857 ↗
74. Sanson C, Diou O, Thévenot J et al (2011) Doxorubicin loaded magnetic polymersomes: theranostic nanocarriers for MR imaging and magneto-chemotherapy. ACS Nano 5(2):1122–114010.1021/nn102762f ↗
75. Amstad E, Kohlbrecher J, Müller E et al (2011) Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett 11(4):1664–167010.1021/nl2001499 ↗
76. Gupta AK, Naregalkar RR, Vaidya VD et al (2007) Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2(1):23–3910.2217/17435889.2.1.23 ↗
77. Gupta AK, Gupta M (2005) Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26(13):1565–157310.1016/j.biomaterials.2004.05.022 ↗
78. Duguet E, Vasseur S, Mornet S et al (2006) Magnetic nanoparticles and their applications in medicine. Nanomedicine 1(2):157–16810.2217/17435889.1.2.157 ↗
79. Gurzau ES, Neagu C, Gurzau AE (2003) Essential metals—case study on iron. Ecotoxicol Environ Saf 56(1):190–20010.1016/S0147-6513(03)00062-9 ↗
80. Elias A, Tourkas A (2009) Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles. Hematology 1:720–72610.1182/asheducation-2009.1.720 ↗
81. Veranth JM, Kaser EG, Veranth MM et al (2007) Cytokine responses of human lung cells (BEAS-2B) treated with micron-sized and nanoparticles of metal oxides compared to soil dusts. Part Fibre Toxicol 4(1):210.1186/1743-8977-4-2 ↗
82. Häfeli UO, Riffle JS, Harris-Shekhawat L et al (2009) Cell uptake and in vitro toxicity of magnetic nanoparticles suitable for drug delivery. Mol Pharmaceutics 6(5):1417–142810.1021/mp900083m ↗
83. Stroh A, Zimmer C, Gutzeit C et al (2004) Iron oxide particles for molecular magnetic resonance imaging cause transient oxidative stress in rat macrophages. Free Radical Biol Med 36(8):976–98410.1016/j.freeradbiomed.2004.01.016 ↗
84. Sadeghiani N, Barbosa LS, Silva LP et al (2005) Genotoxicity and inflammatory investigation in mice treated with magnetite nanoparticles surface coated with polyaspartic acid. J Magn Magn Mater 289:466–46810.1016/j.jmmm.2004.11.131 ↗
85. Ejderyan N, Sanyal R, Sanyal A (2022) Stimuli-responsive polymer-coated iron oxide nanoparticles as drug delivery platforms. In Stimuli-responsive nanocarriers 133–16910.1016/B978-0-12-824456-2.00009-6 ↗
86. Basuki JS, Jacquemin A, Esser L et al (2014) A block copolymer-stabilized co-precipitation approach to magnetic iron oxide nanoparticles for potential use as MRI contrast agents. Polym Chem 5(7):2611–262010.1039/C3PY01778H ↗
87. Herranz F, Salinas B, Groult H et al (2014) Superparamagnetic nanoparticles for atherosclerosis imaging. Nanomaterials 4(2):408–43810.3390/nano4020408 ↗
88. Jensen KMØ, Andersen HL, Tyrsted C et al (2014) Mechanisms for iron oxide formation under hydrothermal conditions: an in situ total scattering study. ACS Nano 8(10):10704–1071410.1021/nn5044096 ↗
89. Kurzhals S, Zirbs R, Reimhult E (2015) Synthesis and magneto-thermal actuation of iron oxide core–PNIPAM shell nanoparticles. ACS Appl Mater Interfaces 7(34):19342–1935210.1021/acsami.5b05459 ↗
90. Chin AB, Yaacob II (2007) Synthesis and characterization of magnetic iron oxide nanoparticles via w/o microemulsion and Massart’s procedure. J Mater Process Technol 191(1):235–23710.1016/j.jmatprotec.2007.03.011 ↗
91. Wang J, Sun J, Sun Q et al (2003) One-step hydrothermal process to prepare highly crystalline Fe3O4 nanoparticles with improved magnetic properties. Mater Res Bull 38(7):1113–111810.1016/S0025-5408(03)00129-6 ↗
92. Mao B, Kang Z, Wang E et al (2006) Synthesis of magnetite octahedrons from iron powders through a mild hydrothermal method. Mater Res Bull 41(12):2226–223110.1016/j.materresbull.2006.04.037 ↗
93. Sun S, Zeng H (2002) Size-controlled synthesis of magnetite nanoparticles. J Am Chem Soc 124(28):8204–820510.1021/ja026501x ↗
94. Lassenberger A, Grünewald TA, van Oostrum PDJ et al (2017) Monodisperse iron oxide nanoparticles by thermal decomposition: elucidating particle formation by second-resolved in situ small-angle X-ray scattering. Chem Mater 29(10):4511–452210.1021/acs.chemmater.7b01207 ↗
95. Park J, An K, Hwang Y et al (2004) Ultra-large-scale syntheses of monodisperse nanocrystals. Nature Mater 3(12):891–89510.1038/nmat1251 ↗
96. Guardia P, Pérez-Juste J, Labarta A et al (2010) Heating rate influence on the synthesis of iron oxide nanoparticles: the case of decanoic acid. Chem Commun 46(33):6108–611010.1039/c0cc01179g ↗
97. Riaz S, Bashir M, Naseem S (2014) Iron oxide nanoparticles prepared by modified co-precipitation method. IEEE Trans Magn 50(1):1–4
98. Kang YS, Risbud S, Rabolt JF et al (1996) Synthesis and characterization of nanometer-size Fe 3 O 4 and γ-Fe 2 O 3 particles. Chem Mater 8(9):2209–221110.1021/cm960157j ↗
99. Bruce IJ, Taylor J, Todd M et al (2004) Synthesis, characterisation and application of silica-magnetite nanocomposites. J Magn Magn Mater 284:145–16010.1016/j.jmmm.2004.06.032 ↗
100. Laurent S, Forge D, Port M et al (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 108(6):2064–211010.1021/cr068445e ↗